How Much Retirement Income Could $100,000 in These 3 Dividend Stocks Generate?
Three companies in pharmaceuticals, energy, and tobacco operate in entirely different worlds, and that separation is exactly the point for retirees who need their income to survive whatever the market throws at one sector.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Retirees who live off a portfolio watch one number more than any other: the cash that lands in the account each quarter. Split $100,000 equally across three large-cap dividend payers, about $33,333.33 in each, and forward dividend rates would produce about $3,973.89 in annual passive income. That is more than $3,950 a year from a single six-figure investment, a combined yield of 3.97%.
The three companies work in pharmaceuticals, energy, and tobacco. Each answers to a different set of forces (drug patents, crude prices, and nicotine demand), so the income rests on cash flows that have little to do with one another. None of these payouts is guaranteed. Boards set dividends, and business results can change them. Below is what a $33,333.33 stake in each name would generate, using forward yields based on share prices from the October 26, 2026 session.
Chevron
- Stock #3: Chevron (NYSE:CVX | CVX Price Prediction)
- Forward Yield: 3.06%
- Shares for $33,333.33: 143.49
- Annual Passive Income: ~$1,021.62
Chevron is an integrated supermajor. It produces oil and gas in the Permian Basin, the Gulf of America, Guyana, and Kazakhstan, then refines and sells fuels, lubricants, and chemicals. Its yield comes from a mature, cash-rich business that returns capital through a steady dividend plus buybacks. The forward payout is $7.12 per share. The yield has fallen because shares are up 56.66% year to date.
Coverage looks solid. Second-quarter adjusted EPS came in at $6.06 against a $1.78 quarterly dividend, and the quarter produced $18.1 billion of free cash flow. Chevron also paid down $8.4 billion of debt and bought back $3.1 billion of stock. Its payout rose from $1.71 to $1.78 per quarter in 2026. Risk: oil prices drive much of that cash flow. Brent averaged $104 per barrel versus $68 a year earlier, and a reversal would squeeze free cash flow.
Philip Morris International
- Stock #2: Philip Morris International (NYSE:PM)
- Forward Yield: 3.18%
- Shares for $33,333.33: 165.44
- Annual Passive Income: ~$1,058.83
Philip Morris sells Marlboro outside the U.S. and runs a fast-growing smoke-free business built on IQOS, ZYN, and VEEV. Smoke-free products made up more than 40% of third-quarter net revenue. The yield reflects the tobacco discount investors apply to the stock, combined with a policy of raising the dividend every year. The latest increase lifted the quarterly payout to $1.60 from $1.47.
Against 2026 adjusted EPS guidance of $8.29 to $8.44, the $6.40 forward dividend works out to a payout ratio of about 77% at the midpoint. Expected operating cash flow of about $13.5 billion is well above planned capex of $1.4 to $1.6 billion. Net debt to adjusted EBITDA fell to 2.17x from 2.53x. Risk: management expects operating income growth to land toward the middle or lower half of its range because of geopolitical cost impacts and the U.S. investment ramp-up.
Pfizer
- Stock #1: Pfizer (NYSE:PFE)
- Forward Yield: 5.68%
- Shares for $33,333.33: 1,100.84
- Annual Passive Income: ~$1,893.44
Pfizer develops and sells prescription medicines and vaccines, including Eliquis, Prevnar, Vyndaqel, and Padcev. Its high yield reflects years of pressure: COVID product sales collapsed, with Paxlovid down 95% operationally, and the company faces patent expirations. Even after a 27.92% year-to-date rise, the stock still yields well above the other two.
The $1.72 annual dividend equals about 59% of the midpoint of confirmed 2026 adjusted EPS guidance of $2.80 to $3.00. Pfizer has also raised its 2026 revenue guidance midpoint by $500 million. The quarterly payout rose from $0.41 in 2023 to $0.43 and has not been cut in the period shown. Risk: generic and biosimilar competition is expected to cost about $1.1 billion in 2026 revenue, and no buybacks are planned while the company reduces debt.
Income Breakdown Across All Three Positions
| Name | Forward Yield | Annual Dividend Income |
|---|---|---|
| Chevron | 3.06% | $1,021.62 |
| Philip Morris International | 3.18% | $1,058.83 |
| Pfizer | 5.68% | $1,893.44 |
| Total | 3.97% | $3,973.89 |
These 3 positions together generate $3,973.89 in annual passive income on a $100,000 investment, a combined yield of 3.97%. Chevron contributes $1,021.62, Philip Morris adds $1,058.83, and Pfizer accounts for $1,893.44.
All three pay quarterly, so the income arrives on a regular schedule. Pfizer’s next payment is due December 7, 2026. For someone covering monthly bills, that steady flow of cash from three unrelated industries can be worth as much as the yield. Investors should watch payout coverage each quarter, since it is the first sign of whether the income will hold up.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
